Posted by Michael Wonder on 02 Aug 2021
Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus
2 August 2021 - Saphnelo is a first in class type I interferon receptor antibody and the only new medicine in over a decade for patients with systemic lupus erythematosus
AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus who are receiving standard therapy.
